Multipurpose Nucleic Acid Degradation
The various types of biological products and pharmaceutical drugs are expanding rapidly. Simultaneously, biological products also have a strict quality control system, among which residual nucleic acid is a key focus of drug regulatory agencies. Products such as AAV vectors, antibody drugs, vaccines, and recombinant protein drugs are expressed and produced by continuously passaged cells. Even after a fine purification process, host nucleic acids may remain in the products, and the residual nucleic acids may cause pathogenicity, tumorigenesis, etc. risk. Additionally, CAR-T cell therapies, lentivirus therapies, protein extraction industries all need to strictly control the residue of nucleic acid.